Revolution Medicines, Inc.
Clinical trials sponsored by Revolution Medicines, Inc., explained in plain language.
Develops targeted therapies for RAS-driven cancers.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill targets Hard-to-Treat cancers with a specific gene mutation Results expected Dec 2026 (estimated)
- New pill targets Hard-to-Treat cancers in early trial Results expected Mar 2027 (estimated)
- New drug cocktails aim to shrink Hard-to-Treat gut cancers Results expected May 2027 (estimated)
- New pill targets Hard-to-Treat cancers with RAS mutations Results expected May 2027 (estimated)
- New hope for Hard-to-Treat lung cancer: targeted drug combo trial launches Results expected Jun 2027 (estimated)
-
Last-Resort drug access opens for advanced pancreatic cancer patients
Disease control ApprovedThis program offers daraxonrasib to adults with metastatic pancreatic cancer that has worsened after prior treatment and who have no other good options. It is for patients who cannot join ongoing clinical trials. The goal is to provide access to this experimental drug when no sta…
Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for pancreatic cancer: targeted drug enters final testing phase
Disease control OngoingThis phase 3 trial tests a new drug called daraxonrasib (RMC-6236) against standard treatments for people with metastatic pancreatic cancer that has already been treated. About 500 adults with a specific RAS gene mutation will be randomly assigned to receive either the new drug o…
Phase 3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called RMC-6291 in adults with advanced cancers (lung, colon, pancreatic) that have a specific KRAS G12C mutation. The goal is to find the safest dose and see how well the drug works. About 222 participants will receive the drug by mouth, a…
Phase 1 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC